Page 60 - MI-2-2

Microbes & Immunity Role of SRCR proteins in inflammation

Long-term therapy with itolizumab is safe and effective admission are associated with in-hospital mortality of septic
for patients with moderate to severe psoriasis: Results patients-A preliminary study. Int J Environ Res Public Health.
from an expanded-access program. Int Immunopharmacol. 2023;20(3):2263.
2024;134:112225.
doi: 10.3390/ijerph20032263
doi: 10.1016/j.intimp.2024.112225
35. Volfovitch Y, Tsur AM, Gurevitch M, et al. The
30. Rodriguez PC, Prada DM, Moreno E, et al. The anti-CD6 intercorrelations between blood levels of ferritin, sCD163,
antibody itolizumab provides clinical benefit without and IL-18 in COVID-19 patients and their association to
lymphopenia in rheumatoid arthritis patients: Results prognosis. Immunol Res. 2022;70(6):817-828.
from a 6-month, open-label Phase I clinical trial. Clin Exp
Immunol. 2018;191(2):229-239. doi: 10.1007/s12026-022-09312-w
doi: 10.1111/cei.13061 36. Thomsen KL, Moller HJ, Graversen JH, et al. Anti-
CD163-dexamethasone conjugate inhibits the acute phase
31. Loganathan S, Athalye SN, Joshi SR. Itolizumab, an response to lipopolysaccharide in rats. World J Hepatol.
anti-CD6 monoclonal antibody, as a potential treatment 2016;8(17):726-730.
for COVID-19 complications. Expert Opin Biol Ther.
2020;20(9):1025-1031. doi: 10.4254/wjh.v8.i17.726
doi: 10.1080/14712598.2020.1798399 37. Etzerodt A, Moulin M, Doktor TK, et al. Tissue-resident
macrophages in omentum promote metastatic spread of
32. Martinez-Florensa M, Consuegra-Fernandez M, Aranda F, ovarian cancer. J Exp Med. 2020;217(4):e20191869.
et al. Protective effects of human and mouse soluble
scavenger-like CD6 lymphocyte receptor in a lethal model doi: 10.1084/jem.20191869
of polymicrobial sepsis. Antimicrob Agents Chemother. 38. Moeller JB, Nielsen MJ, Reichhardt MP, et al. CD163-L1
2017;61(1):e01391-16. is an endocytic macrophage protein strongly regulated
doi: 10.1128/AAC.01391-16 by mediators in the inflammatory response. J Immunol.
2012;188(5):2399-2409.
33. Etzerodt A, Moestrup SK. CD163 and inflammation:
Biological, diagnostic, and therapeutic aspects. Antioxid doi: 10.4049/jimmunol.1103150
Redox Signal. 2013;18(17):2352-2363. 39. Gonzalez-Dominguez E, Samaniego R, Flores-Sevilla JL,
doi: 10.1089/ars.2012.4834 et al. CD163L1 and CLEC5A discriminate subsets of human
resident and inflammatory macrophages in vivo. J Leukoc
34. Mierzchala-Pasierb M, Lipinska-Gediga M, Lewandowski L,
Krzystek-Korpacka M. Alterations in serum concentration Biol. 2015;98(4):453-466.
of soluble CD163 within five study days from ICU doi: 10.1189/jlb.3HI1114-531R

Volume 2 Issue 2 (2025) 52 doi: 10.36922/mi.5741